Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Clinician's Knowledge and Awareness of Patient-Reported Outcomes in Immune Thrombocytopenia: Results of a National Survey (ITP NET, GIMEMA Working Group Anemia and Thrombocytopenia)

Esther Natalie Oliva, Fabio Efficace, Maria Rosa Valvano, Paola Arcuri, Roberta Battistini, Elisa Buzzatti, Cristina Clissa, Cristina Danesin, Alessia Salemme, Francesco Sparano, Federico Chiurazzi

Blood (2024) 144 (Supplement 1): 2440.

https://doi.org/10.1182/blood-2024-205336

Published: 2024

Journal Articles

Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Blood (2024) 144 (Supplement 1): 2464.

https://doi.org/10.1182/blood-2024-204659

Published: 2024

Journal Articles

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Blood (2023) 142 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2023-179922

Published: 2023

Journal Articles

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-138371

Published: 2020

Journal Articles

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Blood (2018) 132 (Supplement 1): 4347.

https://doi.org/10.1182/blood-2018-99-112062

Published: 2018

Journal Articles

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Blood (2018) 132 (Supplement 1): 4365.

https://doi.org/10.1182/blood-2018-99-117714

Published: 2018

Journal Articles

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Erica Tsang, Diego Villa, MD, Federica Loscocco, Alina S Gerrie, MD, Giuseppe Visani, Maryse Power, MB, Barbara Guiducci, Cristina Clissa, MD PhD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc, Kevin W Song, MD, Cindy Toze, Yasser Abou-Mourad, Heather Sutherland, MD, David Sanford, MD, Stephen H Nantel, MD, Laurie H. Sehn, MDMPH, David W. Scott, MD PhD FRACP, FRCPA, Alessandro Isidori, MD PhD

Blood (2017) 130 (Supplement 1): 3291.

https://doi.org/10.1182/blood.V130.Suppl_1.3291.3291

Published: 2017

Journal Articles

Deferasirox Boosts Hematopoietic Recovery after ALLO-Sct

Giuseppe Visani, Claudio Giardini, Federica Loscocco, Barbara Guiducci, Cristina Clissa, MD PhD, Elisa Gabucci, Alessandro Isidori, MD PhD

Blood (2017) 130 (Supplement 1): 5463.

https://doi.org/10.1182/blood.V130.Suppl_1.5463.5463

Published: 2017

Journal Articles

Gene Mutations and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Y Follo, PhD, Andrea Pellagatti, PhD, Richard N Armstrong, PhD, Stefano Ratti, MD, Sara Mongiorgi, PhD, Annalisa Astolfi, PhD, Valentina Indio, PhD, Cristina Clissa, MD PhD, Domenico Russo, MD, Marco Gobbi, MD, Marilena Barraco, PhD, Sarah Parisi, MD PhD, Andrea Pession, MD, Michele Cavo, MD, Lucia Manzoli, MD, Lucio Cocco, MD, Jacqueline Boultwood, PhD, Carlo Finelli, MD

Blood (2017) 130 (Supplement 1): 5299.

https://doi.org/10.1182/blood.V130.Suppl_1.5299.5299

Published: 2017

Journal Articles

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Matilde Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Annalisa Astolfi, PhD, Domenico Russo, MD, Marco Gobbi, MD, Costanza Bosi, MD, Monica Crugnola, MD, Marta Stanzani, MD, Stefano Ratti, MD, Sarah Parisi, MD, Marilena Barraco, PhD, Lucia Manzoli, MD, Andrea Pession, MD, Lucio Cocco, MD, PhD, Carlo Finelli, MD

Blood (2016) 128 (22): 5091.

https://doi.org/10.1182/blood.V128.22.5091.5091

Published: 2016

Journal Articles

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Blood (2016) 128 (22): 3169.

https://doi.org/10.1182/blood.V128.22.3169.3169

Published: 2016

Journal Articles

Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL

Blood (2015) 126 (23): 1999.

https://doi.org/10.1182/blood.V126.23.1999.1999

Published: 2015

Journal Articles

Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes

Blood (2015) 126 (23): 1675.

https://doi.org/10.1182/blood.V126.23.1675.1675

Published: 2015

Journal Articles

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Blood (2015) 126 (23): 2871.

https://doi.org/10.1182/blood.V126.23.2871.2871

Published: 2015

Journal Articles

Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study

Carlo Finelli, MD, Cristina Clissa, MD, Matilde Y Follo, PhD, Marta Stanzani, MD PhD, Paolo Avanzini, Costanza Bosi, MD, Barbara Castagnari, MD, Anna Candoni, MD, Monica Crugnola, MD, Maria Benedetta Giannini, MD, Marco Gobbi, MD, Giovanna Leonardi, MD, Gian Matteo Rigolin, MD, Patrizia Tosi, MD, Giuseppe Visani, MD, Lucio Cocco, MD, Michele Cavo, MD, Domenico Russo, MD PhD

Blood (2014) 124 (21): 4648.

https://doi.org/10.1182/blood.V124.21.4648.4648

Published: 2014

Journal Articles

Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience

Blood (2013) 122 (21): 3911.

https://doi.org/10.1182/blood.V122.21.3911.3911

Published: 2013

Journal Articles

Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)

Matilde Y Follo, PhD, Carlo Finelli, Cristina Clissa, M.D., Sara Mongiorgi, PhD, Carmen Baldazzi, Marta Stanzani, MD, PhD, Michele Baccarani, MD, Lucio Cocco, MD

Blood (2013) 122 (21): 5227.

https://doi.org/10.1182/blood.V122.21.5227.5227

Published: 2013

Journal Articles

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Matilde Y Follo, PhD, Carlo Finelli, MD, Cristina Clissa, MD, Sara Mongiorgi, PhD, Carla Filì, MD, Costanza Bosi, MD, Marilisa Quaranta, PhD, Stefania Paolini, MD, Anna Maria Billi, PhD, Marco Gobbi, MD, Michele Baccarani, MD, Domenico Russo, Giovanni Martinelli, MD, Lucia Manzoli, MD, Lucio Cocco, MD

Blood (2012) 120 (21): 1289.

https://doi.org/10.1182/blood.V120.21.1289.1289

Published: 2012

Journal Articles

Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients

Carlo Finelli, M.D., Cristina Clissa, M.D., Maria Teresa Voso, Maria Antonietta Aloe Spiriti, Massimo Breccia, Gianluca Gaidano, MD, PhD, Monica Crugnola, M.D., Maria Benedetta Giannini, M.D., Costanza Bosi, MD, Virginia Naso, MD, Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Giovanni Martinelli, Lucio Cocco, MD, Michele Baccarani, MD

Blood (2012) 120 (21): 4951.

https://doi.org/10.1182/blood.V120.21.4951.4951

Published: 2012

Journal Articles

Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients

Matilde Y Follo, PhD, Cristina Clissa, MD, Sara Mongiorgi, PhD, Francesca Chiarini, PhD, Michele Baccarani, MD, Giovanni Martinelli, MD, PhD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2011) 118 (21): 4635.

https://doi.org/10.1182/blood.V118.21.4635.4635

Published: 2011

NARROW

Clinician's Knowledge and Awareness of Patient-Reported Outcomes in Immune Thrombocytopenia: Results of a National Survey (ITP NET, GIMEMA Working Group Anemia and Thrombocytopenia)

Reaction - Real Life Use of Ravulizumab in Italian Patients with Paroxysmal Nocturnal Hemoglobinuria a Multicenter Observational Retrospective and Prospective Cohort Study, Final Results

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Azacitidine and Lenalidomide in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study and Impact of Cytogenetic Scores and Mutational Status on Long-Lasting Responses

Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Comparative Effectiveness of High-Dose Bendamustine-EAM Versus BEAM in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Deferasirox Boosts Hematopoietic Recovery after ALLO-Sct

Gene Mutations and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Role of Nuclear Inositide Signalling and microRNA Signature in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in Higher-Risk Myelodysplastic Syndromes. Long-Term Results of a Randomized Phase II Multicenter Study

Benda-BEAM High-Dose Therapy Prior to Auto-SCT Is Effective in Resistant/Relapsed DLBCL

Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes

Association of Azacitidine and Lenalidomide (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes. Final Results of a Randomized Phase II Multicenter Study

Addition of Lenalidomide (LEN) to Azacitidine (AZA) (Combined vs Sequential Treatment) in High-Risk Myelodysplastic Syndromes (MDS): A Randomized Phase II Multicenter Study

Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience

Clonal Effect Of Lenalidomide On Akt Activation In Low-Risk MDS Patients With Del(5q)

Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients

Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients

Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only